Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations (RAMs) in the ODIN study

被引：0
作者：
Arribas, J. [1 ]
Arathoon, E. [2 ]
Gonsalez, C. R. [3 ]
Latiff, G. H. [4 ]
Van De Casteele, T. [5 ]
De Doncker, P. [5 ]
De La Rosa, G. [6 ]
Spinosa-Guzman, S. [5 ]
机构：
[1] Hosp Univ La Paz, IdiPAZ, Madrid, Spain
[2] Clin Familiar Luis Angel Garcia, Guatemala City, Guatemala
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Pinheiros, Brazil
[4] Maxwell Ctr, Durban, South Africa
[5] Tibotec BVBA, Beerse, Belgium
[6] Tibotec Therapeut, Titusville, NJ USA
来源：
ANTIVIRAL THERAPY | 2010年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [41] Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naive and treatment-experienced patients with human immunodeficiency virus-1 infection
    Lathouwers, Erkki
    Seyedkazemi, Sareh
    Luo, Donghan
    Brown, Kimberley
    De Meyer, Sandra
    Wong, Eric Y.
    [J]. HIV RESEARCH & CLINICAL PRACTICE, 2020, 21 (2-3) : 83 - 89
  • [42] The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects
    Ruane, P. J.
    Brinson, C.
    Ramgopal, M.
    Ryan, R.
    Coate, B.
    Cho, M.
    Kakuda, T. N.
    Anderson, D.
    [J]. HIV MEDICINE, 2015, 16 (05) : 288 - 296
  • [43] Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation
    Sahloff, Eric G.
    Duggan, Joan M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (01) : 50 - 55
  • [44] Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 study)
    LaMarca, A
    Clumeck, N
    Plettenberg, A
    Domingo, P
    Fu, KS
    Craig, C
    Zhao, H
    Watson, M
    Gordon, D
    Scott, T
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (05) : 598 - 606
  • [45] Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    Clotet, Bonaventura
    Feinberg, Judith
    van Lunzen, Jan
    Khuong-Josses, Marie-Aude
    Antinori, Andrea
    Dumitru, Irina
    Pokrovskiy, Vadim
    Fehr, Jan
    Ortiz, Roberto
    Saag, Michael
    Harris, Julia
    Brennan, Clare
    Fujiwara, Tamio
    Min, Sherene
    [J]. LANCET, 2014, 383 (9936) : 2222 - 2231
  • [46] Week 48 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in HIV-1-infected adults from the AMBER and EMERALD Phase III trials
    Lathouwers, E.
    Wong, E.
    Brown, K.
    Baugh, B.
    Ghys, A.
    Jezorwski, J.
    Van Landuyt, E.
    Opsomer, M.
    De Meyer, S.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [47] Non-inferior efficacy for darunavir/ritonavir 400/100 mg once daily versus lopinavir/ritonavir, for patients with HIV RNA below 50 copies/mL in South Africa: The 48-week WRHI 052 study
    Venter, F.
    Moorhouse, M.
    Sokhela, S.
    Maharaj, E.
    Akpomiemie, G.
    Simmons, B.
    Serenata, C.
    Hill, A.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 156 - 157
  • [48] Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
    Molina, Jean-Michel
    Clotet, Bonaventura
    van Lunzen, Jan
    Lazzarin, Adriano
    Cavassini, Matthias
    Henry, Keith
    Kulagin, Valeriv
    Givens, Naomi
    de Oliveira, Carlos Fernando
    Brennan, Clare
    [J]. LANCET HIV, 2015, 2 (04): : E127 - E136
  • [49] Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial
    Lathouwers, E.
    Murrow, S.
    Baugh, B.
    Ghys, A.
    Jezorwski, J.
    Mohsine, E. G.
    Opsomer, M.
    De Meyer, S.
    [J]. HIV MEDICINE, 2019, 20 : 97 - 97
  • [50] Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study
    Elion, Richard
    deJesus, Edwin
    Sension, Michael
    Berger, Daniel
    Towner, William
    Richmond, Gary
    Clair, Marty St.
    Yau, Linda
    Ha, Belinda
    [J]. HIV CLINICAL TRIALS, 2008, 9 (03): : 152 - 163
12345